| 1 |
35419921 | In Situ Prodrug Activation by an Affibody-Ruthenium Catalyst Hybrid for HER2-Targeted Chemotherapy. | 2022 Jun 27 |
3 |
| 2 |
35463361 | Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance. | 2022 |
1 |
| 3 |
34407596 | [Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer]. | 2021 Aug 23 |
2 |
| 4 |
31019975 | Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo. | 2019 |
6 |
| 5 |
31407230 | Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). | 2019 Nov |
3 |
| 6 |
31692005 | Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis. | 2019 Dec |
1 |
| 7 |
31774522 | Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. | 2019 Nov 1 |
2 |
| 8 |
26780095 | Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. | 2018 |
3 |
| 9 |
29845287 | Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer. | 2018 Jul |
1 |
| 10 |
28605730 | Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. | 2017 |
1 |
| 11 |
28982882 | Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer. | 2017 Oct |
1 |
| 12 |
25398698 | Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. | 2015 Jan |
1 |
| 13 |
25459391 | Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. | 2015 Jan |
2 |
| 14 |
25821636 | Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. | 2015 Jan |
8 |
| 15 |
25890497 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. | 2015 May 10 |
2 |
| 16 |
25976081 | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 Jul |
11 |
| 17 |
26475267 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 Oct 16 |
4 |
| 18 |
26539407 | Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis. | 2015 Oct |
1 |
| 19 |
24038924 | In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery. | 2014 Jan |
1 |
| 20 |
24799054 | Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. | 2014 Apr |
2 |
| 21 |
25844392 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. | 2014 Apr 9 |
3 |
| 22 |
23444220 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. | 2013 May 15 |
1 |
| 23 |
24394124 | [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer]. | 2013 Nov |
1 |
| 24 |
26225219 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). | 2013 May |
8 |
| 25 |
26251840 | Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. | 2013 |
8 |
| 26 |
22006161 | A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. | 2012 Oct |
1 |
| 27 |
22276821 | Bevacizumab added to neoadjuvant chemotherapy for breast cancer. | 2012 Jan 26 |
2 |
| 28 |
22536237 | Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series. | 2012 |
2 |
| 29 |
23040000 | Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. | 2012 Oct |
1 |
| 30 |
23422737 | Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. | 2012 Mar |
2 |
| 31 |
26225216 | Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. | 2012 Oct |
3 |
| 32 |
21169024 | Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. | 2011 Jan 1 |
11 |
| 33 |
21550422 | Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. | 2011 Dec |
3 |
| 34 |
22084374 | Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. | 2011 Dec 20 |
1 |
| 35 |
20604681 | CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. | 2010 Dec |
1 |
| 36 |
21087480 | Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. | 2010 Nov 18 |
1 |
| 37 |
21143954 | Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report. | 2010 Dec 10 |
1 |
| 38 |
19467571 | Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. | 2009 Nov 18 |
2 |
| 39 |
19661042 | Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. | 2009 Aug |
3 |
| 40 |
19918289 | Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. | 2009 Sep 15 |
1 |
| 41 |
18408445 | [A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy]. | 2008 Apr |
2 |
| 42 |
18505062 | Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. | 2008 Mar-Apr |
2 |
| 43 |
18621615 | Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. | 2008 Apr |
2 |
| 44 |
18685414 | Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. | 2008 Sep |
2 |
| 45 |
18952556 | A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. | 2008 Oct |
1 |
| 46 |
17538166 | Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. | 2007 Jun 1 |
1 |
| 47 |
17555368 | Her signaling in pancreatic cancer. | 2007 Jun |
1 |
| 48 |
18034988 | Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer. | 2007 Nov-Dec |
1 |
| 49 |
16820921 | Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. | 2006 Aug |
1 |
| 50 |
17169763 | Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. | 2006 Dec |
1 |